• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alumis Inc. - Common Stock (NQ:ALMS)

    24.98 +1.12 (+4.69%)
    Streaming Delayed Price Updated: 12:27 PM EST, Jan 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Alumis Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million ↗
    Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    On Thursday, there are stocks with unusual volume. Let's take a look. ↗
    Via Chartmill
    News headline image
    Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today ↗
    Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz. 
    Via Stocktwits
    Topics ETFs Government Stocks
    Unusual volume stocks in Wednesday's session ↗
    Via Chartmill
    Nasdaq, S&P 500 Futures Tread Water Ahead Of ADP Data: Why NVDA, META, APLD, VTYX, ALMS Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Stocks
    Dow Clears 49,000 as AI’s “Data Deluge” Ignites a Memory-Stock Melt-Up ↗
    Via Chartmill
    Topics Artificial Intelligence Stocks
    News headline image
    Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential ↗
    The company also disclosed plans of a $175 million underwritten share offering after releasing its Phase 3 trial data. 
    Via Stocktwits
    News headline image
    Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗
    Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital. 
    Via The Motley Fool
    Topics Stocks
    News headline image
    The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble
    The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation,"... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
    Via AB Newswire
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Tuesday's session. ↗
    Via Chartmill
    News headline image
    Why Is ALMS Stock Rising Today? ↗
    Alumis announced positive results from both of its Phase 3 clinical trials of envudeucitinib. 
    Via Stocktwits
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
    From Alumis Inc.
    Via GlobeNewswire
    News headline image
    Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today ↗
    Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Stocks
    News headline image
    This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
    A full exit during a volatile stretch raises a sharper question than timing alone. 
    Via The Motley Fool
    News headline image
    What's going on in today's session ↗
    Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
    Via Chartmill
    News headline image
    Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session. ↗
    Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
    Via Chartmill
    News headline image
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday ↗
     
    Via Benzinga
    News headline image
    Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Alumis Misses Q2 Revenue as Costs Jump ↗
    Via The Motley Fool
    News headline image
    Top movers in Tuesday's session ↗
    Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
    Via Chartmill
    News headline image
    ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
    From ACELYRIN, INC.
    Via GlobeNewswire
    News headline image
    Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
    ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today 
    From ACELYRIN, INC.
    Via GlobeNewswire
    News headline image
    ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
    From ACELYRIN, INC.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.